Nav: Home

HPV immunization program cuts pre-cancer rates by more than half

October 21, 2019

A school-based human papillomavirus (HPV) immunization program in British Columbia, Canada, is dramatically reducing rates of cervical pre-cancer in B.C. women, according to a new study.

The evaluation of the HPV vaccination program in B.C. was conducted jointly by researchers at BC Cancer, the BC Centre for Disease Control, BC Women's Hospital + Health Centre and the University of British Columbia and highlights the success of the program in reducing pre-cancers. Pre-cancer refers to abnormal cell growth in the cervix most often discovered during routine Pap tests. If not treated, pre-cancer can develop into cervical cancer.

The study found that B.C. women who had received the HPV vaccine as Grade 6 girls had a 57 per cent reduction in the incidence of cervical pre-cancer cells compared to unvaccinated women.

"We are excited by these initial findings," said Dr. Gina Ogilvie, senior research advisor, BC Women's Hospital + Health Centre and professor at the UBC school of population and public health. "This study contributes to the growing body of evidence highlighting the positive impact of the HPV vaccine and regular cervical screening on preventing cervical cancer. And, with increased vaccine uptake, we would expect to see a further decrease in cervical cancer rates."

HPV has been identified as the cause of almost all cervical cancers. In 2008, B.C. implemented a voluntary publicly funded school-based HPV immunization program. Eleven years later, the first groups of women vaccinated through this program have reached adulthood and entered the Cervix Screening Program. By linking records from the provincial Cervix Screening Program with immunization registries, researchers were able to compare outcomes between the women who had received vaccinations to those who had not.

Women included in the study received the quadrivalent vaccine, which protects against two types of HPV responsible for approximately 70 per cent of all cervical cancers. The HPV vaccine that is now administered in the school-based program protects against seven types of the virus that cause about 90 per cent of cervical cancers. As today's Grade 6 girls receive a more comprehensive vaccine, rates of pre-cancer are expected to decline even further in coming years.

HPV is common in both men and women and can be easily spread through sexual contact. Most people will contract HPV at some point in their lives, and it is important to get vaccinated before becoming sexually active. The vaccine is now available for free to both girls and boys in Grade 6 and protects against cervical, anal and some rare penile cancers.

Although most HPV infections clear up on their own, some cause pre-cancerous lesions that can develop into cancer over time if not treated. It can take more than 10 years for pre-cancerous cells to develop into cervical cancer. Regular cervical cancer screening is important to identify abnormal or pre-cancerous cells, before they cause symptoms.

"The HPV immunization program in B.C. is in its 12th year now, and it's very gratifying to be able to show such positive outcomes through prevention of this infection and its complications in women," said Dr. Monika Naus, medical director, communicable diseases and immunization service, and professor at the school of population and public health at the University of British Columbia.
-end-


University of British Columbia

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Meditations on Loneliness
Original broadcast date: April 24, 2020. We're a social species now living in isolation. But loneliness was a problem well before this era of social distancing. This hour, TED speakers explore how we can live and make peace with loneliness. Guests on the show include author and illustrator Jonny Sun, psychologist Susan Pinker, architect Grace Kim, and writer Suleika Jaouad.
Now Playing: Science for the People

#565 The Great Wide Indoors
We're all spending a bit more time indoors this summer than we probably figured. But did you ever stop to think about why the places we live and work as designed the way they are? And how they could be designed better? We're talking with Emily Anthes about her new book "The Great Indoors: The Surprising Science of how Buildings Shape our Behavior, Health and Happiness".
Now Playing: Radiolab

The Third. A TED Talk.
Jad gives a TED talk about his life as a journalist and how Radiolab has evolved over the years. Here's how TED described it:How do you end a story? Host of Radiolab Jad Abumrad tells how his search for an answer led him home to the mountains of Tennessee, where he met an unexpected teacher: Dolly Parton.Jad Nicholas Abumrad is a Lebanese-American radio host, composer and producer. He is the founder of the syndicated public radio program Radiolab, which is broadcast on over 600 radio stations nationwide and is downloaded more than 120 million times a year as a podcast. He also created More Perfect, a podcast that tells the stories behind the Supreme Court's most famous decisions. And most recently, Dolly Parton's America, a nine-episode podcast exploring the life and times of the iconic country music star. Abumrad has received three Peabody Awards and was named a MacArthur Fellow in 2011.